AMR Crisis in India: Why Superbugs Are a Present Reality, Not a Future Threat

Antimicrobial resistance is a severe and present crisis in India, not just a future worry. The country bears one of the world's heaviest AMR burdens, with alarmingly high death rates and resistance levels. Common infections are becoming untreatable as first-line and even last-resort antibiotics lose their effectiveness. While a new national plan offers hope, experts stress urgent action on antibiotic use and infection control is needed now.

Key Points: India Faces Present Reality of Antimicrobial Resistance AMR Crisis

  • India saw 267,000 deaths from drug-resistant infections in 2019, among the highest globally
  • Over 80% of Indian patients carry multidrug-resistant organisms, the highest rate worldwide
  • One in three bacterial infections in India is resistant to common antibiotics, per WHO
  • New national action plan aims to strengthen surveillance and curb antibiotic misuse
3 min read

Why is antimicrobial resistance not just future threat, but a present reality

Expert warns AMR is a present crisis in India, with 267,000 deaths in 2019 and 80% of patients carrying multidrug-resistant organisms.

"AMR is not a future threat but rather a present reality in India. - Florian von Groote, Wellcome Trust"

New Delhi, Dec 8

Antimicrobial Resistance (AMR) is not just a threat for the future, but a present reality affecting millions of people across the globe, particularly India, said Florian von Groote, Head of Clinical Research, at Wellcome Trust Infectious Disease Clinical Research Team, UK, on Monday.

Speaking to IANS, von Groote, an infectious disease expert, shared that AMR is one of the top global health issues causing millions of infections and deaths each year. India, with its large population, high infectious disease burden, and widespread antibiotic use, remains disproportionally affected.

"AMR is no longer a hospital-only issue but rather affects every day healthcare in India. These trends reflect widespread antibiotic misuse, gaps in infection control, and poor surveillance in many parts of the country. AMR is not a future threat but rather a present reality in India," he said.

India continues to face some of the world's highest burdens of bacterial infections.

According to a recent World Health Organization (WHO) report, about one in three bacterial infections in India were resistant to commonly used antibiotics in 2023. Globally, it was one in six confirmed infections.

National AMR surveillance data also show troubling resistance patterns in pathogens such as E. coli, Klebsiella pneumoniae, Staphylococcus aureus, and Acinetobacter baumannii.

A recent study, published in the Lancet eClinical Medicine journal, warned that India is at the epicentre of a superbug explosion as several patients in the country were found to carry multiple highly resistant organisms simultaneously.

It showed that more than 80 per cent of Indian patients carry multidrug-resistant organisms (MDROs) -- the highest globally.

von Groote noted that attention to AMR is rising because common infections are becoming harder to treat, antibiotics are failing, and the economic impact can no longer be ignored.

"Resistance levels to certain key antibiotics are indeed alarmingly high. Therapeutic options are shrinking, and many first-line and even last-line antimicrobials are losing effectiveness, resulting in previously easily manageable infections being difficult or impossible to treat," von Groote told IANS.

"India carries one of the heaviest antimicrobial resistance burdens in the world. In 2019, the country saw an estimated 267,000 deaths directly caused by drug-resistant infections, placing it among the highest contributors to global AMR deaths," the infectious disease expert added, citing data from joint research from Oxford University, UK, and the University of Washington, US.

While ICMR's latest data indicate a modest improvement in E. coli susceptibility to ceftazidime (from 19.2 per cent in 2023 to 27.5 per cent in 2024), rising resistance to carbapenems and colistin remains a red flag, signalling diminishing treatment options in the country.

"Compared with other populous countries in Asia and Africa, India remains a critical hotspot... due to sheer size, high infection load, and widespread antibiotic misuse," von Groote said.

Notably, to contain antibiotic resistance, the Ministry of Health and Family Welfare launched the second version of the National Action Plan on Antimicrobial Resistance (2025-29) with key strategies.

The NAP-AMR 2.0 addresses the gaps identified in the first NAP-AMR by increasing the ownership of AMR-related efforts, strengthening intersectoral coordination, and ensuring stronger engagement with the private sector through a One Health approach.

Meanwhile, von Groote suggested rational and responsible use of antibiotics; better surveillance across humans, animals, and the environment; and a push to develop novel drugs, vaccines, and diagnostics.

The expert also mentioned simple measures such as hand hygiene and other infection control practices to reduce the need for antibiotics.

- IANS

Share this article:

Reader Comments

R
Rohit P
The government's new action plan is a good step, but implementation is key. We've seen plans fail before due to poor monitoring. Public awareness campaigns are crucial—people need to stop demanding antibiotics for every small cough and cold from their doctors.
A
Aman W
It's not just about human medicine. The article mentions a 'One Health' approach. The rampant use of antibiotics in poultry and dairy farming is a huge part of the problem. We are consuming these drugs indirectly through our food.
S
Sarah B
As someone who has worked in public health, I appreciate this article highlighting the data. 267,000 deaths in 2019 is a staggering number. This needs to be treated with the same urgency as other major health crises. The economic impact on families and the country will be devastating.
V
Vikram M
While the expert's points are valid, I feel the article places a disproportionate burden on India. Yes, we have issues, but this is a global problem born from decades of overuse worldwide. Pharmaceutical innovation has also slowed down. The solution requires global cooperation, not just finger-pointing at high-burden countries.
N
Nisha Z
Simple hygiene! We learned this during COVID. Washing hands properly can prevent so many infections and reduce the need for antibiotics in the first place. Schools and offices should have mandatory hygiene protocols. It's a low-cost, high-impact solution.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50